Sigyn Therapeutics, Inc. (SIGY)
USD 4.15
(0.0%)
USD 4.15
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.45 Million USD | 14.35% |
| 2022 | 2.14 Million USD | 6.92% |
| 2021 | 2 Million USD | 119.13% |
| 2020 | 916.43 Thousand USD | 46.49% |
| 2019 | 625.61 Thousand USD | -38.87% |
| 2018 | 1.02 Million USD | -68.08% |
| 2017 | 3.2 Million USD | 116.46% |
| 2016 | 1.48 Million USD | -34.82% |
| 2015 | 2.27 Million USD | 460.47% |
| 2014 | 405.44 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 628.44 Thousand USD | -12.38% |
| 2024 Q2 | 601.44 Thousand USD | -4.08% |
| 2023 Q2 | 574 Thousand USD | 10.12% |
| 2023 Q1 | 521.25 Thousand USD | 10.53% |
| 2023 FY | 2.44 Million USD | 13.93% |
| 2023 Q4 | 717.23 Thousand USD | 11.58% |
| 2023 Q3 | 642.81 Thousand USD | 11.99% |
| 2022 Q3 | 533.64 Thousand USD | 0.16% |
| 2022 Q4 | 471.58 Thousand USD | -11.63% |
| 2022 FY | 2.14 Million USD | 6.92% |
| 2022 Q1 | 609.23 Thousand USD | 3.1% |
| 2022 Q2 | 532.79 Thousand USD | -12.55% |
| 2021 FY | 2 Million USD | 119.13% |
| 2021 Q3 | 573.36 Thousand USD | 29.77% |
| 2021 Q1 | 402.09 Thousand USD | -40.98% |
| 2021 Q2 | 441.81 Thousand USD | 9.88% |
| 2021 Q4 | 590.93 Thousand USD | 3.07% |
| 2020 FY | 916.43 Thousand USD | 46.49% |
| 2020 Q1 | 90.92 Thousand USD | -29.42% |
| 2020 Q3 | 89.61 Thousand USD | 64.24% |
| 2020 Q2 | 54.56 Thousand USD | -39.99% |
| 2020 Q4 | 681.33 Thousand USD | 660.32% |
| 2019 Q2 | 148.81 Thousand USD | -26.02% |
| 2019 Q1 | 201.15 Thousand USD | 147.45% |
| 2019 FY | 625.61 Thousand USD | -38.87% |
| 2019 Q4 | 128.82 Thousand USD | -12.25% |
| 2019 Q3 | 146.81 Thousand USD | -1.34% |
| 2018 Q3 | 346.54 Thousand USD | -29.95% |
| 2018 Q4 | -423.96 Thousand USD | -222.34% |
| 2018 Q1 | 606.08 Thousand USD | -43.96% |
| 2018 Q2 | 494.67 Thousand USD | -18.38% |
| 2018 FY | 1.02 Million USD | -68.08% |
| 2017 Q2 | 862.59 Thousand USD | 60.6% |
| 2017 FY | 3.2 Million USD | 116.46% |
| 2017 Q4 | 1.08 Million USD | 46.61% |
| 2017 Q3 | 737.72 Thousand USD | -14.48% |
| 2017 Q1 | 537.09 Thousand USD | -46.08% |
| 2016 Q4 | 996.04 Thousand USD | 202.34% |
| 2016 Q3 | 329.44 Thousand USD | -37.47% |
| 2016 Q1 | 712.67 Thousand USD | -12.23% |
| 2016 Q2 | 526.88 Thousand USD | -26.07% |
| 2016 FY | 1.48 Million USD | -34.82% |
| 2015 Q1 | 159.56 Thousand USD | 20.58% |
| 2015 Q4 | 811.95 Thousand USD | -0.56% |
| 2015 FY | 2.27 Million USD | 460.47% |
| 2015 Q3 | 816.55 Thousand USD | 65.04% |
| 2015 Q2 | 494.77 Thousand USD | 210.08% |
| 2014 Q3 | 87.1 Thousand USD | 0.0% |
| 2014 FY | 405.44 Thousand USD | 0.0% |
| 2014 Q4 | 132.33 Thousand USD | 51.92% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -83.86% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 51.303% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 91.692% |
| Nascent Biotech, Inc. | 2.22 Million USD | -10.11% |
| Rebus Holdings, Inc. | 664 Thousand USD | -269.777% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 93.41% |
| Qrons Inc. | 643.67 Thousand USD | -281.452% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -530.27% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 95.725% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -490.961% |
| Skye Bioscience, Inc. | 13.54 Million USD | 81.876% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.171% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 50.074% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -838.125% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.132% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 15.805% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -63.481% |
| Mesoblast Limited | 5.9 Million USD | 58.399% |
| Marizyme, Inc. | 19.23 Million USD | 87.238% |
| Genus plc | 147.7 Million USD | 98.338% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 72.033% |
| Pharming Group N.V. | 225.49 Million USD | 98.911% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -19.847% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -83.022% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 70.556% |
| ContraFect Corporation | 56.88 Million USD | 95.684% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 44.307% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -66.04% |
| IMV Inc. | 37.7 Million USD | 93.489% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 12.007% |
| MultiCell Technologies, Inc. | 567.42 USD | -432615.978% |
| ONE Bio Corp. | 6.44 Million USD | 61.897% |
| Accustem Sciences Inc. | 3.74 Million USD | 34.462% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.143% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -361.559% |
| Q BioMed Inc. | 3.43 Million USD | 28.554% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 90.065% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 6.554% |
| Biomind Labs Inc. | 994.18 Thousand USD | -146.969% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.528% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -39.532% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 63.452% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -31.697% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 9921.268% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 84.664% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -33.798% |
| GB Sciences, Inc. | 1.42 Million USD | -72.848% |
| Alpha Cognition Inc. | 9.7 Million USD | 74.702% |
| HST Global, Inc. | 140.9 Thousand USD | -1642.509% |
| CSL Limited | 3.44 Billion USD | 99.929% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -118.268% |
| Halberd Corporation | 74.84 Thousand USD | -3180.667% |
| Enzolytics Inc. | 2.17 Million USD | -12.655% |
| Agentix Corp. | 1.37 Million USD | -78.991% |
| Resverlogix Corp. | 12.71 Million USD | 80.685% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 32.744% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.84% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -135.184% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -2.095% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -55.463% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 27.89% |
| AVAX Technologies, Inc. | 7.31 Million USD | 66.413% |
| Zenith Capital Corp. | 8.94 Million USD | 72.545% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.703% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -13994.007% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1331.597% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -27.821% |
| Kadimastem Ltd | 2.41 Million USD | -1.876% |
| Helix BioMedix, Inc. | 1.97 Million USD | -24.507% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 77.406% |
| BioStem Technologies, Inc. | 22.97 Million USD | 89.313% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1252.904% |
| LadRx Corporation | 3.81 Million USD | 35.586% |
| Cell Source, Inc. | 4.32 Million USD | 43.234% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -165.868% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -165.868% |
| NovAccess Global Inc. | 2.46 Million USD | 0.464% |
| Affymax, Inc. | 39.38 Million USD | 93.766% |
| Itoco Inc. | 919.14 Thousand USD | -167.131% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 42.07% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -119.421% |
| Mobile Lads Corp. | 554.54 Thousand USD | -342.762% |
| CytoDyn Inc. | 18.05 Million USD | 86.403% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -9655.322% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1015.658% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -72.935% |
| SYBLEU INC | 160.87 Thousand USD | -1426.217% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -35.181% |
| International Stem Cell Corporation | 5.27 Million USD | 53.418% |
| Bioxytran, Inc. | 3.82 Million USD | 35.727% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4564.179% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -11969.592% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.23% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -51.75% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -233.678% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 21.076% |
| Neutra Corp. | 243.82 Thousand USD | -907.016% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 85.935% |
| PureTech Health plc | 144.59 Million USD | 98.302% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 88.017% |
| IXICO plc | 4.7 Million USD | 47.837% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 72.089% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.915% |
| CSL Limited | 3.89 Billion USD | 99.937% |
| Cellectis S.A. | 97.32 Million USD | 97.477% |